JP7846007B2 - 異常ヘモグロビン症の治療用組成物及び方法 - Google Patents

異常ヘモグロビン症の治療用組成物及び方法

Info

Publication number
JP7846007B2
JP7846007B2 JP2022536699A JP2022536699A JP7846007B2 JP 7846007 B2 JP7846007 B2 JP 7846007B2 JP 2022536699 A JP2022536699 A JP 2022536699A JP 2022536699 A JP2022536699 A JP 2022536699A JP 7846007 B2 JP7846007 B2 JP 7846007B2
Authority
JP
Japan
Prior art keywords
sequence
cells
molecule
grna
cas9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506842A (ja
JP2023506842A5 (cg-RX-API-DMAC7.html
Inventor
ブリュー,ムルケン
ブラドナー,ジェームズ
ストロカ コブ,ジェニファー
ルース,カーステン
シゴイロット,フレデリック
スティーブンソン,スーザン,シー.
ティン,パメラ
ボナッツィ,シモン
サーニジェンコ,アーチョム
デイルズ,ナタリー
ライアン ケリガン,ジョン
ラム,フィリップ
アフマド マリク,ハスネイン
トムセン,ノエル,マリー‐フランス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023506842A publication Critical patent/JP2023506842A/ja
Publication of JP2023506842A5 publication Critical patent/JP2023506842A5/ja
Priority to JP2026060998A priority Critical patent/JP2026126214A/ja
Application granted granted Critical
Publication of JP7846007B2 publication Critical patent/JP7846007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022536699A 2019-12-18 2020-12-16 異常ヘモグロビン症の治療用組成物及び方法 Active JP7846007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060998A JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962950025P 2019-12-18 2019-12-18
US201962950048P 2019-12-18 2019-12-18
US62/950,048 2019-12-18
US62/950,025 2019-12-18
PCT/IB2020/001098 WO2021123920A1 (en) 2019-12-18 2020-12-16 Compositions and methods for the treatment of hemoglobinopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060998A Division JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Publications (3)

Publication Number Publication Date
JP2023506842A JP2023506842A (ja) 2023-02-20
JP2023506842A5 JP2023506842A5 (cg-RX-API-DMAC7.html) 2024-10-16
JP7846007B2 true JP7846007B2 (ja) 2026-04-14

Family

ID=74701511

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022536699A Active JP7846007B2 (ja) 2019-12-18 2020-12-16 異常ヘモグロビン症の治療用組成物及び方法
JP2026060998A Pending JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026060998A Pending JP2026126214A (ja) 2019-12-18 2026-04-02 異常ヘモグロビン症の治療用組成物及び方法

Country Status (5)

Country Link
US (1) US20230279394A1 (cg-RX-API-DMAC7.html)
EP (1) EP4077676A1 (cg-RX-API-DMAC7.html)
JP (2) JP7846007B2 (cg-RX-API-DMAC7.html)
CN (1) CN115176005A (cg-RX-API-DMAC7.html)
WO (1) WO2021123920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250179531A1 (en) * 2022-02-25 2025-06-05 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
CN116445402B (zh) * 2023-05-09 2025-04-25 中国科学院生态环境研究中心 红系祖细胞的扩增培养基、扩增培养方法及应用
US12385408B1 (en) * 2024-01-26 2025-08-12 Rtx Corporation Life and performance improvement trenches

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
ATE237353T1 (de) 1992-05-05 2003-05-15 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendung
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖rna仲介遺伝子抑制
AU2004305111B2 (en) 2003-12-19 2011-04-28 Novartis Vaccines And Diagnostics, Inc. Cell transfecting formulations of small interfering RNA, related compositions and methods of making and use
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
US9394547B2 (en) 2012-01-03 2016-07-19 City University Of Hong Kong Method and apparatus for delivery of molecules to cells
US20130178421A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP2968295A1 (en) 2013-03-15 2016-01-20 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
PL2970948T3 (pl) 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Sposoby oczyszczania rna
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3129485B2 (en) * 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2018071871A1 (en) 2016-10-13 2018-04-19 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
US20180135080A1 (en) * 2016-11-15 2018-05-17 Genomic Vision Sa Method for the monitoring of modified nucleases induced-gene editing events by molecular combing
US20180305719A1 (en) * 2017-04-19 2018-10-25 The Board Of Trustees Of The University Of Illinois Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
EP3731849A4 (en) * 2017-12-28 2021-12-01 Codiak BioSciences, Inc. EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ivan KRIVEGA et al.,Blood,2015年,Vol. 126, No. 5,pp. 665-672
Jeremy M. SIMON et al.,Journal of Biological Chemistry,2015年,Vol. 290, No. 43,pp. 26088-26102
Martin KARL et al.,Journal of Molecular Biology,2019年09月,Vol. 431,pp. 3606-3625

Also Published As

Publication number Publication date
JP2023506842A (ja) 2023-02-20
EP4077676A1 (en) 2022-10-26
WO2021123920A1 (en) 2021-06-24
US20230279394A1 (en) 2023-09-07
JP2026126214A (ja) 2026-08-04
CN115176005A (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
JP7844400B2 (ja) 異常ヘモグロビン症の治療用組成物および方法
US20230018543A1 (en) Crispr/cas-mediated gene conversion
KR102630217B1 (ko) 혈색소병증의 치료를 위한 조성물 및 방법
JP2025020189A (ja) 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法
US11512311B2 (en) Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
US20170007679A1 (en) Crispr/cas-related methods and compositions for treating hiv infection and aids
EP3129485A2 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
US20230279394A1 (en) Compositions and methods for the treatment of hemoglobinopathies
HK40080440A (en) Compositions and methods for the treatment of hemoglobinopathies
BR112018013065B1 (pt) Molécula de grna, composições, sequência de ácidos nucléicos, vetor, seus respectivos usos
BR122021012712B1 (pt) Molécula de grna, composições, sequência de ácidos nucleicos, vetor, seus respectivos usos, método de alteração de células ex vivo, uso destas, e método de preparação de população de células
BR122021012669B1 (pt) Molécula de grna, composições, sequência de ácidos nucleicos, vetor, seus respectivos usos, método de alteração de células ex vivo, uso destas, e método de preparação de população de células

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260402

R150 Certificate of patent or registration of utility model

Ref document number: 7846007

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150